Medisch Spectrum Twente
- Address
- lock Available on a paid plan
Immune System & Rheumatic Research
The Reumatologie department at Medisch Spectrum Twente advances care for patients with immune system diseases and related musculoskeletal conditions, testing innovative biologic agents and refining treatment strategies to improve quality of life.
- Rheumatoid arthritis
- Psoriatic arthritis
- Axial spondyloarthritis
- Sjögren's Disease
- Skin and connective tissue disorders
Ongoing trials evaluate safety, efficacy, and cost‑effectiveness of new DMARDs and targeted therapies, positioning the site as a hub for rheumatology innovation.
Cancer and Hematology Trials
Research at the hospital spans a broad range of neoplasms and hematologic malignancies, focusing on novel drug combinations, immunotherapies, and personalized approaches to extend survival and enhance tolerability.
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Breast Cancer (including triple‑negative)
- Colorectal Cancer and liver metastases
- Melanoma (cutaneous and metastatic)
- Ovarian Cancer (including platinum‑resistant)
- Pancreatic Cancer (resectable and metastatic)
The site’s oncology program integrates cutting‑edge immuno‑oncology trials and evaluates maintenance strategies to improve long‑term outcomes.
Cardiovascular & Metabolic Studies
The centre conducts extensive work on cardiovascular diseases and metabolic disorders, investigating therapies that reduce events such as myocardial infarction, heart failure, and peripheral arterial disease while addressing obesity‑related risk.
- Acute myocardial infarction (STEMI/NSTEMI)
- Chronic heart failure with preserved ejection fraction
- Atrial fibrillation
- Peripheral arterial disease
- Atherosclerotic cardiovascular disease
- Obesity and metabolic syndrome
Trials test lipid‑lowering antibodies, anti‑inflammatory agents, and novel dosing regimens to lower major adverse cardiovascular events.
Respiratory and Infectious Disease Trials
Focused investigations target respiratory tract diseases and serious infections, aiming to improve acute care and chronic management through new therapeutics and diagnostic tools.
- Acute Respiratory Distress Syndrome (ARDS)
- Chronic Obstructive Pulmonary Disease
- Severe eosinophilic asthma
- Respiratory syncytial virus infection
- Sepsis and community‑acquired pneumonia
Studies evaluate anti‑inflammatory peptides, monoclonal antibodies, and adaptive platform designs to accelerate effective treatment discovery.
Digestive System and Liver Research
The department addresses digestive system diseases ranging from inflammatory bowel conditions to complex oncologic surgeries, seeking to refine peri‑operative care and novel systemic therapies.
- Inflammatory bowel disease
- Chronic pancreatitis
- Pancreatic head carcinoma (resectable and borderline)
- Colorectal cancer with liver metastases
- Hepatic arterial infusion chemotherapy
Trials compare neoadjuvant regimens, assess pain‑relief strategies, and explore biomarker‑guided approaches to improve surgical outcomes.
Diagnostic and Therapeutic Technologies
Leveraging advanced analytical, diagnostic and therapeutic techniques, the site integrates imaging, biomarker profiling, and surgical innovations to support precision medicine across specialties.
- Integrated omics for treatment response prediction
- High‑resolution imaging for tumor resection margins
- Novel surgical devices and operative protocols
- Real‑time monitoring of inflammatory markers
- Platform trials evaluating multiple interventions simultaneously
These technology‑focused studies enhance trial efficiency and patient safety, reinforcing Medisch Spectrum Twente’s role as a leader in clinical innovation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 20 therapeutic areas and 15 of 216 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 211 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1Amsterdam UMC Stichting9active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amsterdam UMC Stichting12trials
lock +18 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medisch Spectrum Twente
lock Showing 1 of 109 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis | Alfasigma S.p.A. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 216 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 9 | Unknown | 2020-12-18 | 2026-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.